ReviewFrontiers in oncology2026
The evolving role of radiotherapy in oligometastatic pancreatic cancer: from palliation to disease-modifying multidisciplinary integration.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligometastatic pancreatic ductal adenocarcinoma (PDAC) may benefit from aggressive multidisciplinary therapy, yet the role of stereotactic body radiotherapy (SBRT) remains controversial and frameworks for patient selection remain incompletely defined. While SBRT has become a standard option in oligometastatic lung and prostate cancer, its application in PDAC faces unique challenges related to tumor biology, anatomic constraints, and a paucity of randomized evidence. This narrative review searched PubMed, Embase, and Cochrane Library (January 2000-May 2026) for English-language studies addressing PDAC, oligometastases, and SBRT. Of 1,247 records screened, 186 studies were included. Six domains were systematically examined: patient selection integrating clinical, molecular, and metabolic imaging biomarkers; pancreas-specific SBRT technical considerations including dose-fractionation and organ-at-risk constraints; systemic therapy integration and sequencing; clinical outcomes and progression patterns; quality-of-life evidence; and ongoing prospective clinical trials. Available evidence from predominantly retrospective series suggests 1-year local control rates of 70-80% for pancreatic primary tumors, 85-95% for lung metastases, and >95% for lymph node metastases, with median overall survival of 12-18 months after SBRT-based consolidative therapy. Emerging biomarkers-including ctDNA dynamics, KRAS mutational subtypes, and transcriptomic classifiers-and advanced technologies such as MR-guided adaptive SBRT and proton therapy show promise for improving the therapeutic ratio. The TREX1/cGAS-STING axis provides a mechanistic rationale for combining SBRT with immune checkpoint inhibitors, though dedicated quality-of-life data remain absent from the literature. Radiotherapy in oligometastatic PDAC has evolved from a purely palliative modality to a disease-modifying component of multidisciplinary care. Prospective validation through pancreas-specific randomized trials incorporating biomarker-driven patient selection and patient-reported outcomes is essential to define the optimal role of SBRT in this setting. Fang Fang and Peng Zhen contributed equally and are co-corresponding authors. Jiarui Zhang and Siming Shi contributed equally to this work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.